Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Assets (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Non-Current Assets for 16 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 34.8% to $141.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $829.2 million through Dec 2025, down 3.08% year-over-year, with the annual reading at $141.7 million for FY2025, 34.8% down from the prior year.
  • Non-Current Assets hit $141.7 million in Q4 2025 for Vanda Pharmaceuticals, down from $233.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $233.6 million in Q3 2025 to a low of $105.0 million in Q3 2023.
  • Historically, Non-Current Assets has averaged $157.7 million across 5 years, with a median of $121.5 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 102.53% in 2024 and later tumbled 34.8% in 2025.
  • Year by year, Non-Current Assets stood at $115.5 million in 2021, then fell by 0.46% to $115.0 million in 2022, then soared by 87.46% to $215.5 million in 2023, then grew by 0.84% to $217.3 million in 2024, then crashed by 34.8% to $141.7 million in 2025.
  • Business Quant data shows Non-Current Assets for VNDA at $141.7 million in Q4 2025, $233.6 million in Q3 2025, and $229.8 million in Q2 2025.